Lexicon Pharmaceuticals CEO Lonnel Coats' 2019 pay jumps 24% to $3.9M
Lexicon Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: March 13, 2020
Lexicon Pharmaceuticals reported fiscal year 2019 executive compensation information on March 13, 2020.
In 2019, seven executives at Lexicon Pharmaceuticals received on average a compensation package of $1.8M, a 18% increase compared to previous year.
Average pay of disclosed executives at Lexicon Pharmaceuticals
Lonnel Coats, Chief Executive Officer, received $3.9M in total, which increased by 24% compared to 2018. 39% of Coats' compensation, or $1.5M, was in option awards. Coats also received $459K in bonus, $649K in salary, $1.2M in stock awards, as well as $12K in other compensation.
For fiscal year 2019, the median employee pay was $185,046 at Lexicon Pharmaceuticals. Therefore, the ratio of Lonnel Coats' pay to the median employee pay was 21 to one.
Praveen Tyle, Executive Vice President, Research and Development, received a compensation package of $1.7M, which increased by 14% compared to previous year. 30% of the compensation package, or $510K, was in option awards.
Jeffrey L. Wade, Chief Financial Officer, earned $1.6M in 2019, a 15% increase compared to previous year.
Pablo Lapuerta, Chief Medical Officer, received $1.5M in 2019, which increases by 16% compared to 2018.
Alexander A. Santini, Former Executive Vice President and Chief Commercial Officer, earned $1.5M in 2019, a 18% increase compared to previous year.
Alan J. Main, Executive Vice President, Innovation and Chemical Sciences, received $1.4M in 2019, which increases by 14% compared to 2018.
Brian T. Crum, General Counsel, earned $933K in 2019, a 20% increase compared to previous year.
Related executives
Lonnel Coats
Lexicon Pharmaceuticals
Chief Executive Officer
Jeffrey Wade
Lexicon Pharmaceuticals
Chief Financial Officer
Brian Crum
Lexicon Pharmaceuticals
General Counsel
Alan Main
Lexicon Pharmaceuticals
Executive Vice President, Innovation and Chemical Sciences
Praveen Tyle
Lexicon Pharmaceuticals
Executive Vice President, Research and Development
Pablo Lapuerta
Lexicon Pharmaceuticals
Chief Medical Officer
Alexander Santini
Lexicon Pharmaceuticals
Former Executive Vice President and Chief Commercial Officer
You may also like
Source: SEC filing on March 13, 2020.